Jasper Therapeutics stock names interim finance leaders after CFO exit
Published on 09/30/2026 at 20:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Jasper Therapeutics stock is dealing with a finance leadership reset after CFO Herb Cross resigned effective October 9, 2026, while the latest quarterly loss was USD 2.76 million. A September 23, 2026 filing outlined the transition and the board's interim appointments.
Finance leadership changes
According to the SEC filing, Cross resigned as chief financial officer, principal financial officer, principal accounting officer and corporate secretary to pursue other professional endeavors. The board appointed President and CEO Jeet Mahal as interim principal financial officer, Rick Ruiz as interim principal accounting officer and COO Matthew Ros as interim corporate secretary.
The company describes itself as a clinical-stage biotechnology business developing therapies for immune-mediated diseases. Its pipeline includes KP-104, briquilimab and KP-701, according to Jasper Therapeutics.
Q2 loss and cash position
For the quarter ended June 30, 2026, Jasper reported a net loss of USD 2.76 million, compared with USD 26.70 million in the same quarter of 2025. The USD 23.94 million reduction gives the latest results a materially different loss profile than the prior-year period.
Cash and cash equivalents stood at USD 7.31 million on June 30, 2026, while total assets were USD 11.80 million and stockholders' equity was USD 1.41 million. The figures were reported in the Q2 filing summary published by StockTitan.
Nasdaq valuation and target
JSPR was trading at USD 0.61 on Nasdaq on September 30, 2026 at 2:49 p.m. ET. Its market capitalization was USD 9.9 million, and its 52-week range was USD 0.32 to USD 2.69, placing the stock well below its yearly high.
StockAnalysis lists analyst Emily Bodnar as reiterating a Buy rating on September 21, 2026, with a USD 20.00 price target. That target sits against a company valued below USD 10 million in the latest market snapshot, highlighting the wide gap between market value and analyst expectations.
Stock reference on September 30
Jasper Therapeutics shares were last at USD 0.61 on Nasdaq on September 30, 2026 at 2:49 p.m. ET, with 155,255 shares traded. The stock's current financial profile combines a narrower Q2 loss with USD 7.31 million in cash and USD 1.41 million in equity.
Jasper Therapeutics at a glance
- Company: Jasper Therapeutics, Inc.
- Ticker: JSPR
- Primary exchange: Nasdaq
- Nasdaq price as of September 30, 2026, 2:49 p.m. ET: USD 0.61
- Market capitalization: USD 9.9 million as of September 30, 2026
- 52-week range: USD 0.32-USD 2.69 as of September 30, 2026
- Sector / Industry: Healthcare / Biotechnology
